Drugs / MVA-PEV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04990479 | Jun 2021 → Mar 2024 | cutaneous melanoma, non-small cell lung carcinoma | Nouscom SRL | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-PEV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04990479 ↗ |
| Modality | Vaccine | “The PEV vaccines will be prepared on an individual basis” NCT04990479 ↗ |
| Route | Intramuscular | “Both neoantigen-encoding genetic vaccines are administered intramuscularly” NCT04990479 ↗ |